Furthermore, the high expression of TIM-3 in metastatic NSCLC helps develop resistance to nivolumab (an anti-PD-1 mAb), and the combination of nivolumab and an anti-TIM-3 mAb may be considered a therapeutic strategy for metastatic NSCLC (64). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.